Project
MK-3475-091; PEARLS
Ongoing - recruitment closed · 2016 until 2099
Fehr Martin, Demmer-Steingruber Ruth, Müller Fiona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2016
End Date
2099
Financing
Industry
Labels
lung cancer
Brief description/objective
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)